Rivastigmine containing external patch and preparation process thereof

Abstract

The invention discloses a rivastigmine containing external patch and a preparation process thereof. The external patch is formed by uniform mixing of the following components by weight: 100 parts of rivastigmine, 10-50 parts of poloxamer, 300-800 parts of water, and 800-1500 parts of a water emulsion type polyacrylate pressure sensitive adhesive. The specific preparation process includes: dissolving rivastigmine and poloxamer in water, then adding the water emulsion type polyacrylate pressure sensitive adhesive, and mixing the materials evenly, coating an anti-sticking layer with the drug-adhesive mixed solution evenly, performing heating drying at 40DEG C-70DEG C, and conducting compounding with a backing film; and carrying out slitting, die cutting and packaging, thus obtaining the external patch. The rivastigmine containing external patch provided by the invention performs transdermal drug delivery, releases drug evenly, and has mild and lasting effect. The preparation process provided by the invention is simple, reduces the production cost, and does not generate environmental pollution. Also, the rivastigmine containing external patch has the advantages of strong adhesion, no irritation to skin, no redness and swelling or itching phenomenon, good patient compliance, and convenient use and carrying.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to a medicinal patch for external use, in particular to a patch for external use containing rivastigmine and a preparation process thereof. Background technique [0002] Alzheimer's disease (Alzheimer`sDisease, AD) is a primary gray matter encephalopathy, often occurs in the elderly. The incidence rate increases with age. The incidence rate is 3.0% for 65-74 years old, 18.7% for 75-84 years old, and 47.2% for those older than 85 years old. It is estimated that 22 million people will suffer from AD in the world after 25 years, and the number of AD patients will increase to 45 million by 2050. Therefore, elucidating the pathogenesis of AD and establishing its treatment plan is a problem that people should solve as soon as possible. According to research, cholinergic hypofunction can lead to cognitive dysfunction, and the cholinergic mechanism may invo...

AI Technical Summary

Problems solved by technology

[0007] The purpose of the present invention is to solve the shortcomings of the original traditional patch, such as skin irritation, the use of organic solvents during production, and damage to the environment and the human body.

Images